Administration of<unk>  should be avoided in individuals with the following: * Known hypersensitivity to<unk>  (absolute contraindication) * Patients under 15 years of age (no sufficient clinical data) * Concomitant treatment with irreversible MAO inhibitors (e.g. tranylcypromine (Parnate), phenelzine (Nardil), >10 mg selegiline) or digitalis glycosides is an absolute contraindication. Administration of<unk>  should be done with caution in individuals with the following: * Concomitant treatment with parenteral epinephrine, norepinephrine, with clonidine, reversible MAO-A Inhibitors (such as moclobemide, toloxatone) or 5-HT1D-agonists (e.g. triptan migraine drugs) * Advanced renal disease (decreased dosage required) * Hypertrophy of the prostate gland (possibly urination hesitancy induced), with hypertension and heart disease (tachycardia may be a problem) as well as with open angle glaucoma.<unk>  should not be used during pregnancy because it may cross the placenta barrier and no clinical data exists on harmful effects in humans and animal studies.<unk>  is contraindicated during lactation because it is excreted in the milk, and it is not known if it is harmful to the newborn.
Milnacipran
Levomilnacipran
Tezacaftor
Damoctocog alfa pegol
Glysobuzole
Amivantamab
Naloxegol
Glybuzole